Safety and immunogenicity of intradermal administration of fractional dose CoronaVac^®, ChAdOx1 nCoV-19 and BNT162b2 as primary series vaccination.

ABSTRACT: There is a limited supply of COVID-19 vaccines, with less than 20% of eligible populations in low-income countries having received one dose. Intradermal delivery of fractional dose vaccines is one way to improve global vaccine access, but no studies have reported data on intradermal delivery of COVID-19 primary series vaccination. We conducted a pilot study to examine the safety and immunogenicity of three intradermal primary series regimens - heterologous regimen of CoronaVac and ChAdOx1 (CoronaVac-ChAdOx1), homologous regimen of ChAdOx1 (ChAdOx1-ChAdOx1), and homologous regimen of BNT162b2 (BNT162b2-BNT162b2). Each dose was 1/5^th or 1/6^th of the standard dose. Two additional exploratory arms of intradermal vaccination for the second dose following an intramuscular f

SUBMITTER: Chatsiricharoenkul S 

PROVIDER: S-EPMC9577032 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature